## **Special Issue**

# Biomarkers in Hepatocellular Carcinoma

#### Message from the Guest Editors

Hepatocellular Carcinoma (HCC) is the sixth most common cancer and the third cancer-related cause of death, with more than 800,000-related deaths each year. In such a complicated scenario, tools for early diagnosis and prognosis prediction are fundamental for patient stratification. HCC early diagnosis is currently achieved by ultrasound screening in cirrhotic patients, accompanied by evaluation in alpha-fetoprotein (AFP) fluctuation over time. However, this screening strategy is far from perfect, especially considering that even patients with liver disease and without advanced fibrosis can develop HCC. With advances in the understanding of tumor biology, along with the development of cellular and molecular techniques, the use of biomarkers related to early detection, invasiveness, metastasis, and recurrence have attracted a great deal of investigative interest resulting in the identification and utilization of several novel markers in this disease. This Special Issue will address the current advances in biomarkers in HCC.

#### **Guest Editors**

Prof. Dr. Lory Saveria Croce'

Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy

Dr. Mauro Giuffrè

Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy

#### Deadline for manuscript submissions

closed (30 April 2022)



## **Diagnostics**

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



mdpi.com/si/62585

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

mdpi.com/journal/diagnostics





## **Diagnostics**

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



### **About the Journal**

#### Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

#### Editor-in-Chief

#### Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

#### **Journal Rank:**

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

